^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Rectal Cancer

    Related cancers:
    1d
    A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis (clinicaltrials.gov)
    P=N/A, N=180, Completed, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Trial completion date: Sep 2029 --> Dec 2025 | Trial primary completion date: Sep 2027 --> Sep 2025 | Enrolling by invitation --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    1d
    Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer (clinicaltrials.gov)
    P=N/A, N=430, Recruiting, M.D. Anderson Cancer Center | Suspended --> Recruiting
    Enrollment open • HEOR
    1d
    TOWER-2: Intraoperative Rectal Lavage to Prevent Local Recurrence After Laparoscopic Mid-to-Low Rectal Cancer Resection: A Multicenter Randomized Trial (clinicaltrials.gov)
    P=N/A, N=1598, Recruiting, Sun Yat-sen University
    New trial
    1d
    GALENOS 1 in Head and Neck, Lung, and Rectal Cancer Patients (clinicaltrials.gov)
    P=N/A, N=110, Recruiting, Fondazione del Piemonte per l'Oncologia
    New trial
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CCL22 (C-C Motif Chemokine Ligand 22) • IL13 (Interleukin 13) • IL15 (Interleukin 15) • IL4 (Interleukin 4) • IL5 (Interleukin 5)
    2d
    Safety and feasibility of combined transanal total mesorectal excision with delayed coloanal anastomosis in high-risk patients with low rectal cancer. (PubMed, Tech Coloproctol)
    TaTME with DCAA was associated with a lower incidence of AL and avoidance of stoma-related morbidity compared with ICAA and diverting ileostomy, while maintaining comparable functional outcomes in high-risk patients with low rectal cancer.
    Journal
    |
    CRP (C-reactive protein)
    2d
    Colonic Intramural Injections of Botulin toxin versus placebo to treat fragmented defecation and urgency after restorative total mesorectal excision (TME) for rectal cancer (2025-524342-96-00)
    P1/2, N=20, Not yet recruiting, UZ Leuven
    New P1/2 trial
    4d
    Predicting Pathological Complete Response in Rectal Cancer Using Machine Learning (clinicaltrials.gov)
    P=N/A, N=320, Active, not recruiting, Peking University People's Hospital
    New trial
    4d
    Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • capecitabine • Jelmyto (mitomycin urothelial gel) • fluorouracil topical • ABP 206 (nivolumab biosimilar)
    4d
    Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance (clinicaltrials.gov)
    P2, N=29, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Tyvyt (sintilimab) • capecitabine • Aidixi (disitamab vedotin)
    6d
    HIF-1α and PD-L1 as Predictive Efficacy Marker for Neoadjuvant Chemoradiotherapy in Rectal Cancer. (PubMed, World J Surg)
    HIF-1α and PD-L1 expression can serve as reliable indicators for predicting NCRT efficacy and poor prognosis in RC patients.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    PD-L1 expression • PD-L1 overexpression
    6d
    Gastric and Rectal Administration of Encorafenib with Targeted Chemotherapy against BRAF V600E-Mutant Rectal Cancer with Bowel Obstruction. (PubMed, Oncologist)
    Targeted inhibition with the oral BRAF inhibitor encorafenib, combined with intravenous cetuximab targeting epithelial growth factor receptor (EGFR) and standard chemotherapy FOLFOX, has improved outcomes and received FDA approval in 2025 based on results from the phase III BREAKWATER trial...This case demonstrates that rectal and nasogastric administration of encorafenib is feasible, achieves therapeutic plasma concentrations, and induces objective and clinical remission in context of FOLFOX+EC. Short-term safety appeared manageable, though increased infection risk cannot be excluded.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    Erbitux (cetuximab) • 5-fluorouracil • Braftovi (encorafenib) • leucovorin calcium